ReviewNature reviews. Gastroenterology & hepatology2013
Pharmacological agents for NASH.
Review in Nature reviews. Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Trial
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.Lancet (London, England) · 2015Trial
- Nitro Fatty Acids (NOMolecules (Basel, Switzerland) · 2021Review
- Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Article
- Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.Redox biology · 2019Article
- Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.PloS one · 2018Article
- The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus.Diabetology international · 2017Article
- Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Molecular therapy. Methods & clinical development · 2017Article
- Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.Lipids in health and disease · 2017Article
- Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.Journal of clinical and translational research · 2017Article
- Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats.Scientific reports · 2017Article
- Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation.International journal of clinical and experimental pathology · 2017Article
- Recombinant SFRP5 protein significantly alleviated intrahepatic inflammation of nonalcoholic steatohepatitis.Nutrition & metabolism · 2017Article
- Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.Alimentary pharmacology & therapeutics · 2016Review
- Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.Visceral medicine · 2016Review
- The role of the gut microbiota in NAFLD.Nature reviews. Gastroenterology & hepatology · 2016Review
- Task-based optimization of flip angle for fibrosis detection in T1-weighted MRI of liver.Journal of medical imaging (Bellingham, Wash.) · 2016Article
- The Immune Landscape in Nonalcoholic Steatohepatitis.Immune network · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NASH is a common liver disease that increases liver-related mortality and reduces survival. The need for optimal management of NASH is therefore a priority for today's practicing hepatologist. The rationale for specific pharmacological therapy for NASH is based on the potential for disease progression and the difficulties that many patients have successfully implementing, in the long term, diet and lifestyle changes. Even in those that succeed, limited evidence exists that severe liver injury in patients with NASH can be reversed by diet and lifestyle measures alone. This Review provides a personal and critical assessment of the histological efficacy and safety of agents tested in randomized trials in patients with NASH.
Indexed as
Identifiers
24126564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.